Risk of liver cancer in HFE-hemochromatosis

Authors

John K. Olynyk, Edith Cowan UniversityFollow
Grant A. Ramm

Author Identifier

John Olynyk

ORCID : 0000-0003-0417-3411

Document Type

Other

Publication Title

Gastroenterology

PubMed ID

34419460

Publisher

Elsevier

School

School of Medical and Health Sciences

RAS ID

36686

Comments

Olynyk, J. K., & Ramm, G. A. (2021). Risk of liver cancer in HFE-hemochromatosis. Gastroenterology, 161(5), 1718-1719. https://doi.org/10.1053/j.gastro.2021.08.025

Abstract

Atkins et al conducted a study examining the community incidence of hepatic malignancy in 451,186 UK Biobank participants of European ancestry and stratified them by carriage of C282Y and H63D variants in the HFE gene (JAMA 2020;324:2048–2057). This study has its background in exploring the clinical penetrance of HFE hemochromatosis. The most common cause of HFE hemochromatosis is C282Y homozygosity, which affects 0.5%–0.6% of individuals of northern European descent. Although studies prior to discovery of the underlying genetic defect reported a significant association of clinically diagnosed hemochromatosis with liver disease and liver cancer, there were limited contemporary data reporting liver-related outcomes, thus justifying the current population study.

DOI

10.1053/j.gastro.2021.08.025

Access Rights

free_to_read